TCR affinity for p/MHC formed by tumor antigens that are self-proteins: Impact on efficacy and toxicity

Jennifer D. Stone, Daniel T. Harris, David M. Kranz

Research output: Contribution to journalReview article

Abstract

Recent studies have shown that the range of affinities of T cell receptors (TCRs) against non-mutated cancer peptide/class I complexes are lower than TCR affinities for foreign antigens. Raising the affinity of TCRs for optimal activity of CD8 T cells, and for recruitment of CD4 T cell activity against a class I antigen, provides opportunities for more robust adoptive T cell therapies. However, TCRs with enhanced affinities also risk increased reactivity with structurally related self-peptides, and off-target toxicities. Careful selection of tumor peptide antigens, in silico proteome screens, and in vitro peptide specificity assays will be important in the development of the most effective, safe TCR-based adoptive therapies.

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalCurrent Opinion in Immunology
Volume33
DOIs
StatePublished - Apr 1 2015

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'TCR affinity for p/MHC formed by tumor antigens that are self-proteins: Impact on efficacy and toxicity'. Together they form a unique fingerprint.

  • Cite this